Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN R130*||Her2-receptor negative breast cancer||predicted - resistant||Alpelisib + Letrozole||Case Reports/Case Series||Actionable||In a Phase I/II trial, combination of Piqray (Alpelisib) and Femara (letrozole) resulted in no clinical benefit in a patient with hormone receptor positive, ERBB2 (HER2)-negative breast cancer harboring PTEN R130* (PMID: 32864625; NCT01870505).||32864625|
|PTEN R130*||thyroid gland follicular carcinoma||sensitive||Akt Inhibitor (Pan)||MK2206||Preclinical - Cell culture||Actionable||In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an follicular thyroid cancer cell line harboring PTEN R130* and loss of one PTEN allele (PMID: 21289267).||21289267|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|